These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37574784)

  • 1. Canada and the pharmaceutical industry in the time of COVID-19.
    Lexchin J
    Int J Soc Determinants Health Health Serv; 2023 Oct; 53(4):508-517. PubMed ID: 37574784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
    Eccleston-Turner M; Upton H
    Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap.
    Borges LC; Zeferino de Menezes H; Crosbie E
    Int J Health Policy Manag; 2022 Dec; 11(12):3101-3113. PubMed ID: 36028975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders.
    Kohler J; Wong A; Tailor L
    Health Hum Rights; 2022 Dec; 24(2):159-175. PubMed ID: 36579316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic.
    Eren Vural I; Herder M; Doll A; Graham JE
    Int J Health Policy Manag; 2023; 12():6936. PubMed ID: 37579382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State capture through indemnification demands? Effects on equity in the global distribution of COVID-19 vaccines.
    Gorodensky A; Kohler JC
    J Pharm Policy Pract; 2022 Aug; 15(1):50. PubMed ID: 35986397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risky business: COVAX and the financialization of global vaccine equity.
    Stein F
    Global Health; 2021 Sep; 17(1):112. PubMed ID: 34544439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response.
    Braimoh T; Burrone E; Gore C; Vijayaraghavan P
    Global Health; 2024 Jul; 20(1):52. PubMed ID: 38956614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Intellectual Property the COVID-19 Bad Guy? Lessons We Could Learn from the Pandemic.
    Lawson C
    J Law Med; 2023 Dec; 30(3):538-554. PubMed ID: 38332594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.
    Park SP; Lee HJ; Yu Y; Lee EYJ; Park YS
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 38035734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pandemics, intellectual property and 'our economy': A worldview analysis of Canada's role in compromising global access to COVID-19 vaccines.
    Brisbois B; Plamondon K; Walugembe D; Pereira RC; Edet C; Dixon J; Habibi R; Karamouzian M; Labonté R; Murthy S; Ravitsky V
    Glob Public Health; 2024 Jan; 19(1):2335360. PubMed ID: 38626321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charity or empowerment? The role of COVAX for low and middle-income countries.
    Holzer F; Roa TM; Germani F; Biller-Andorno N; Luna F
    Dev World Bioeth; 2023 Mar; 23(1):59-66. PubMed ID: 35307947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing the Morality of Owning and Suspending Patent Rights for COVID-19 Vaccines in the Light of Catholic Social Teaching.
    Ballano VO
    Linacre Q; 2022 Feb; 89(1):47-63. PubMed ID: 35321490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical Industry's Engagement in the Global Equitable Distribution of COVID-19 Vaccines: Corporate Social Responsibility of EUL Vaccine Developers.
    Sung M; Huang Y; Duan Y; Liu F; Jin Y; Zheng Z
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID-19: too many cooks or too many recipes?
    Geiger S; McMahon A
    J Med Ethics; 2023 Aug; 49(8):583-590. PubMed ID: 34848492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness.
    Amin T; Kesselheim AS
    Inquiry; 2022; 59():469580221124821. PubMed ID: 36124939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.